MARIA CASSIA JACINTHO MENDES CORREA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina - Líder
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
conferenceObject Implementation of a hepatitis C elimination plan with a view on access expansion and integrality of viral hepatitis care(2018) ALMEIDA, E. C.; CORREA, R. G.; RICK, F. M.; CATTAPAN, E. B.; SANTOS, M. E.; VIVALDINI, S. M.; SOUZA, N. F. de; GOMES, J. N. N.; CORREA, M. C. J. M.; PEREIRA, M. F. C.; PINTO, F. K. A.; RIBEIRO, R. A.; SERENO, L. S.; BENZAKEN, A. S.- Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in Sao Paulo state(2018) MOREIRA, Regina Celia; SANTOS, Ana Paula de Torres; LISBOA-NETO, Gaspar; MENDES-CORREA, Maria Cassia Jacintho; LEMOS, Marcilio Figueiredo; MALTA, Fernanda Mello; SANTANA, RAbia Anita Ferraz; DASTOLI, Gregorio Tadeu Fernando; CASTRO, Vanessa Fusco Duarte de; PINHO, Joao Renato RebelloHepatitis C (HCV)-infected patients are treated with direct-acting antiviral agents (DAAs) in highly effective, well-tolerated, all-oral regimens. However, naturally occurring resistance-associated amino acid substitutions (RASs) may be selected during treatment. This study aimed to screen naturally occurring RASs NS3/NS4A inhibitors (PIs). Samples were obtained from DAA naive patients, living in Sao Paulo state, Brazil. Screening for RASs in the HCV NS3 region was conducted in 859 samples from HCV-infected patients, of which 425 and 434 samples were subtype la and lb, respectively. HCV-RNA was extracted, amplified, and sequenced. The overall prevalence of RASs to HCV PIs was 9.4%. The following RASs were observed in HCV-1a subtype infected patients: V36L (2.6%), T54S (1.6%), V55I/A (1.2% / 8.9%, respectively), Q80K (2.1%), R155K (0.5%), and D168E (0.2%); and in HCV-1b infected patients: V36L (0.7%), T54A/S (0.2% and 0.5%, respectively), V55A (0.5%), Q80K (0.2%), D168E (1.6%), and M175L (0.5%). HCV la infected subjects had higher serum viral load than that seen in patients infected with HCV 1b. There was no difference between the proportions of NS3 RASs with regards to geographic distribution within the investigated areas. These findings should be supported by additional studies in Brazil to help in the formation of local clinical guidelines for managing hepatitis C.
- Potential effect of Zika virus infection on human male fertility?(2018) AVELINO-SILVA, Vivian Lida; ALVARENGA, Conrado; ABREU, Carolina; TOZETTO-MENDOZA, Tania Regina; CANTO, Cynthia Liliane Motta do; MANULI, Erika Regina; MENDES-CORREA, Maria Cassia; SABINO, Ester Cerdeira; FIGUEIREDO, Walter Manso; SEGURADO, Aluisio Cotrim; MAYAUD, PhilippeBackground: Zika virus (ZIKV) sexual transmission and prolonged viral shedding in semen have been previously reported, suggesting a strong viral affinity for genital tissues. A transient impact of ZIKV on male fertility was shown in animal and human studies. Methods: Adult male patients with confirmed ZIKV infection diagnosed in the city of Araraquara, Brazil during the epidemic season of 2016 were invited one year after the acute infection to respond to a questionnaire of genital symptoms and to provide a semen sample for molecular ZIKV testing and spermogram analysis, as well as a serum sample for hormonal testing. Results: 101 of 187 tested patients had positive ZIKV RT-PCR in plasma and/or urine samples (54%. 72 women and 29 men). Of 15 adult male participants for whom telephone contact was successful, 14 responded to the questionnaire of genital symptoms and six consented to provide a semen sample at a median of 12 months after the acute infection. We report abnormal spermogram results from patients one year after confirmed ZIKV infection. Conclusions: Our findings suggest a possible long-term detrimental effect of ZIKV infection on human male fertility that has to be further explored in well-characterized samples from cohort studies conducted in ZIKV-endemic areas.
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study(2018) RAZAVI-SHEARER, Devin; GAMKRELIDZE, Ivane; NGUYEN, Mindie H.; CHEN, Ding-Shinn; DAMME, Pierre Van; ABBAS, Zaigham; ABDULLA, Maheeba; RACHED, Antoine Abou; ADDA, Danjuma; AHO, Inka; AKARCA, Ulus; ALI, Fuad Hasan Al; LAWATI, Faryal Al; NAAMANI, Khalid Al; ALASHGAR, Hamad Ibrahim; ALAVIAN, Seyed M.; ALAWADHI, Sameer; ALBILLOS, Agustin; AL-BUSAFI, Said A.; ALEMAN, Soo; ALFALEH, Faleh Z.; ALJUMAH, Abdulrahman A.; ANAND, Anil C.; Nguyen Thu Anh; ARENDS, Joop E.; ARKKILA, Perttu; ATHANASAKIS, Kostas; BANE, Abate; BEN-ARI, Ziv; BERG, Thomas; BIZRI, Abdul R.; BLACH, Sarah; MELLO, Carlos E. Brandao; BRANDON, Samantha M.; BRIGHT, Bisi; BRUGGMANN, Philip; BRUNETTO, Maurizia; BUTI, Maria; CHAN, Henry L. Y.; CHAUDHRY, Asad; CHIEN, Rong-Nan; CHOI, Moon S.; CHRISTENSEN, Peer B.; CHUANG, Wan-Long; CHULANOV, Vladimir; CLAUSEN, Mette R.; COLOMBO, Massimo; CORNBERG, Markus; COWIE, Benjamin; CRAXI, Antonio; CROES, Esther A.; CUELLAR, Diego Alberto; CUNNINGHAM, Chris; DESALEGN, Hailemichael; DRAZILOVA, Sylvia; DUBERG, Ann-Sofi; EGEONU, Steve S.; EL-SAYED, Manal H.; ESTES, Chris; FALCONER, Karolin; FERRAZ, Maria L. G.; FERREIRA, Paulo R.; FLISIAK, Robert; FRANKOVA, Sona; GAETA, Giovanni B.; GARCIA-SAMANIEGO, Javier; GENOV, Jordan; GERSTOFT, Jan; GOLDIS, Adrian; GOUNTAS, Ilias; GRAY, Richard; PESSOA, Mario Guimaraes; HAJARIZADEH, Behzad; HATZAKIS, Angelos; HEZODE, Christophe; HIMATT, Sayed M.; HOEPELMAN, Andy; HRSTIC, Irena; HUI, Yee-Tak T.; HUSA, Petr; JAHIS, Rohani; JANJUA, Naveed Z.; JARCUSKA, Peter; JAROSZEWICZ, Jerzy; KAYMAKOGLU, Sabahattin; KERSHENOBICH, David; KONDILI, Loreta A.; KONYSBEKOVA, Aliya; KRAJDEN, Mel; KRISTIAN, Pavol; LALEMAN, Wim; LAO, Wai-cheung C.; LAYDEN, Jen; LAZARUS, Jeffrey V.; LEE, Mei-Hsuan; LIAKINA, Valentina; LIM, Young-Suk S.; LOO, Ching-kong K.; LUKSIC, Boris; MALEKZADEH, Reza; MALU, Abraham O.; MAMATKULOV, Adkhamjon; MANNS, Michael; MARINHO, Rui T.; MATICIC, Mojca; MAUSS, Stefan; MEMON, Muhammad S.; CORREA, Maria C. Mendes; MENDEZ-SANCHEZ, Nahum; MERAT, Shahin; METWALLY, Ammal M.; MOHAMED, Rosmawati; MOKHBAT, Jacques E.; MORENO, Christophe; MOSSONG, Joel; MOURAD, Fadi H.; MULLHAUPT, Beat; MURPHY, Kimberly; MUSABAEV, Erkin; NAWAZ, Arif; NDE, Helen M.; NEGRO, Francesco; NERSESOV, Alexander; Van Thi Thuy Nguyen; NJOUOM, Richard; NTAGIRABIRI, Renovat; NURMATOV, Zuridin; OBEKPA, Solomon; OCAMA, Ponsiano; OGUCHE, Stephen; OMEDE, Ogu; OMUEMU, Casimir; OPARE-SEM, Ohene; OPIO, Christopher K.; ORMECI, Necati; PAPATHEODORIDIS, George; PASINI, Ken; PIMENOV, Nikolay; POUSTCHI, Hossein; QUANG, Tran D.; QURESHI, Huma; RAMJI, Alnoor; RAZAVI-SHEARER, Kathryn; REDAE, Berhane; REESINK, Henk W.; RIOS, Cielo Yaneth; RJASKOVA, Gabriela; ROBBINS, Sarah; ROBERTS, Lewis R.; ROBERTS, Stuart K.; RYDER, Stephen D.; SAFADI, Rifaat; SAGALOVA, Olga; SALUPERE, Riina; SANAI, Faisal M.; SANCHEZ-AVILA, Juan F.; SARASWAT, Vivek; SARRAZIN, Christoph; SCHMELZER, Jonathan D.; SCHRETER, Ivan; SCOTT, Julia; SEGUIN-DEVAUX, Carole; SHAH, Samir R.; SHARARA, Ala I.; SHARMA, Manik; SHIHA, Gamal E.; SHIN, Tesia; SIEVERT, William; SPERL, Jan; STARKEL, Peter; STEDMAN, Catherine; SYPSA, Vana; TACKE, Frank; TAN, Soek S.; TANAKA, Junko; TOMASIEWICZ, Krzysztof; URBANEK, Petr; MEER, Adriaan J. van der; VLIERBERGHE, Hans Van; VELLA, Stefano; VINCE, Adriana; WAHEED, Yasir; WAKED, Imam; WALSH, Nicholas; WEIS, Nina; WONG, Vincent W.; WOODRING, Joseph; YAGHI, Cesar; YANG, Hwai-I; YANG, Chung-Lin; YESMEMBETOV, Kakharman; YOSRY, Ayman; YUEN, Man-Fung; YUSUF, Muhammed Aasim M.; ZEUZEM, Stefan; RAZAVI, HomieBackground The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment. Methods In this modelling study, we used a Delphi process that included a literature review in PubMed and Embase, followed by interviews with experts, to quantify the historical epidemiology of HBV infection. We then used a dynamic HBV transmission and progression model to estimate the country-level and regional-level prevalence of HBsAg in 2016 and the effect of prophylaxis and treatment on disease burden. Findings We developed models for 120 countries, 78 of which were populated with data approved by experts. Using these models, we estimated that the global prevalence of HBsAg in 2016 was 3.9% (95% uncertainty interval [UI] 3.4-4.6), corresponding to 291 992 000 (251 513 000-341 114 000) infections. Of these infections, around 29 million (10%) were diagnosed, and only 4.8 million (5%) of 94 million individuals eligible for treatment actually received antiviral therapy. Around 1.8 (1.6-2.2) million infections were in children aged 5 years, with a prevalence of 1.4% (1.2-1.6). We estimated that 87% of infants had received the three-dose HBV vaccination in the first year of life, 46% had received timely birth-dose vaccination, and 13% had received hepatitis B immunoglobulin along with the full vaccination regimen. Less than 1% of mothers with a high viral load had received antiviral therapy to reduce mother-to-child transmission. Interpretation Our estimate of HBV prevalence in 2016 differs from previous studies, potentially because we took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time. Although some regions are well on their way to meeting prophylaxis and prevalence targets, all regions must substantially scale-up access to diagnosis and treatment to meet the global targets. Funding John C Martin Foundation.
conferenceObject Elimination of hepatitis C in Brazil is cost-saving(2018) BENZAKEN, A.; GIRADE, R.; RAZAVI, H.; SCHMELZER, J.; FERRAZ, M. L.; FERREIRA, P. A.; PESSOA, M. G.; MARTINELLI, A.; CATAPAN, E.; SOUTO, F.; CORREA, M. C. M.- Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis(2018) PESSOA, Mario G.; V, Jose Ramalho-Madruga; ALVES, Katia; NUNES, Estevao P.; CHEINQUER, Hugo; BRANDAO-MELLO, Carlos E.; MENDES-CORREA, Maria C.; FERRAZ, Maria L.; FERREIRA, Paulo R. A.; ALVARES-DA-SILVA, Mario R.; COELHO, Henrique S.; AFFONSO-DE-ARAUJO, Evaldo S.; FURTADO, Juvencio; PARANA, Raymundo; SILVA, Giovanni; LARI, Sara A.; LIU, Li; TRIPATHI, Rakesh; PILOT-MATIAS, Tami; COHEN, Daniel E.; SHULMAN, Nancy S.; MARTINELLI, AnaIntroduction and aim. Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) in an openlabel multicenter phase 3b trial in treatment-naive or interferon (IFN) treatment-experienced Brazilian patients with advanced hepatic fibrosis (METAVIR F3/4) and HCV genotype (GT) 1 infection. Material and methods. All patients received coformulated OBV/PTV/r daily + DSV twice daily (3-DAA). GT1a-infected patients received 3-DAA plus RBV for 12 weeks, except for prior pegIFN/RBV nonresponders with cirrhosis who were treated for 24 weeks. GT1b-infected patients received 3-DAA alone (F3) or in combination with RBV (F4) for 12 weeks. The primary endpoint was sustained virologic response (HCV RNA < 15 IU/mL) at post-treatment Week 12 (SVR12). Results. The study enrolled 222 patients, 214 achieved an SVR 12 (96.4%; 95% CI, 93.1-98.2%), one GT1a-infected patient experienced virologic breakthrough, six (5 GT1a) relapsed, and one was lost to follow-up. SVR 12 was achieved in 111/112 (99.1%) GT1b-infected patients, including 42/43 (97.7%) noncirrhotic, and 69/69 (100%) cirrhotic patients; and in 103/110 (93.6%) GT1a-infected patients, including 44/46 (95.7%) noncirrhotic and 59/64 (92.2%) cirrhotic patients. Overall there was a low rate of serious adverse events (n = 6, 2.7%). One patient experienced a treatment-related serious adverse event and one patient discontinued treatment because of an adverse event. Discussion. The results confirm that the 3-DAA regimen with/without RBV is well tolerated and had a favorable safety profile and is efficacious in GT1-infected patients with advanced fibrosis (METAVIR F3/4).
- Hepatitis C elimination by 2030 is feasible in Brazil: a mathematical modelling approach(2018) BENZAKEN, A.; CATAPAN, E.; GIRADE, R.; RAZAVI, H.; SCHMELZER, J.; PESSOA, M.; FERRAZ, M. L.; FERREIRA, P.; MARTINELLI, A.; CORREA, M. C. M.
- Serological and molecular markers of hepatitis E virus infection in HIV-infected patients in Brazil(2018) FERREIRA, A. C.; GOMES-GOUVEA, Michele Soares; LISBOA-NETO, G.; MENDES-CORREA, M. C. J.; PICONE, C. M.; SALLES, N. A.; MENDRONE-JUNIOR, A.; CARRILHO, F. J.; PINHO, J. R. R.In Brazil, the circulation of hepatitis E virus (HEV) has been demonstrated in distinct groups of individuals and some animals, but its prevalence among individuals with human immunodeficiency virus (HIV) infection is unknown. This study aimed to assess the frequency of serological and molecular HEV markers in individuals infected with HIV from So Paulo, Brazil. Serum and plasma samples of 354 HIV-infected patients collected between 2007 and 2013 were included. All samples were tested for anti-HEV IgG and IgM antibodies and HEV RNA. Anti-HEV IgG and IgM antibodies were detected in 10.7% (38/354) and 1.4% (5/354) of the samples, respectively. Both antibodies were detected simultaneously in only two samples. HEV RNA was not detected in any sample. There was no significant correlation of anti-HEV serological status (positivity to anti-HEV IgG and/or IgM) with sex, age, CD4(+) T cell count, HIV viral load, antiretroviral therapy, liver enzyme levels, or coinfection with hepatitis B virus and/or hepatitis C virus. Our study provides serological evidence of past and recent HEV infections in HIV-infected patients from So Paulo, Brazil. However, the occurrence of ongoing HEV infection appears be a rare event in this population.
- Fluctuations in serological hepatitis C virus levels in HIV patients(2018) SILVA, Vanessa Cristina Martins; CALUX, Samira Julien; LEMOS, Marcilio Figueiredo; COMPRI, Adriana Parise; SANTOS, Ana Paula de Torres; OBA, Isabel Takano; MENDES-CORREA, Maria Cassia Jacintho; MOREIRA, Regina CeliaIntroduction: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) have identical transmission routes, explaining the high prevalence of coinfections. The main aim of this study was to detect fluctuations in serological HCV levels in HIV patients. Methods: We analyzed samples of 147 patients who attended an outpatient service that supports HIV/AIDS patients in Sao Paulo city. We also recruited 22 HCV-monoinfected patients who attended the Instituto Adolfo Lutz Laboratory in Sao Paulo city, to compare the test results. Serological testing of the blood samples was performed for the detection of HCV antibodies. The samples were then analyzed using real-time PCR for RNA viral quantification and sequencing. Results: We found that 13.6% of the study population was coinfected with HIV and HCV. In 20% of coinfected patients, fluctuations in serology results were detected in samples collected during the follow-up. No changes in anti-HCV serological markers were observed in HCV-monoinfected patients. An HCV viral load was detected in 9,5% of the samples collected from HIV patients. Conclusions: Our findings provide important clinical data to public health professionals and highlight the importance of periodic monitoring of HCV/HIV coinfected patients.